Time to Progression by Organ with Lenvatinib Plus + Pembrolizumab in Advanced RCC.

Opinion
Video

Panelists discuss time to progression by organ with lenvatinib plus + pembrolizumab in advanced renal cell carcinoma (RCC), highlighting key data and its the implications for treatment decisions.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts in this video
2 experts in this video
2 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
2 experts in this video
Related Content